Assertio (ASRT) Stock Price, News & Analysis

Company Overview

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Key Stats

• Today's Range: $0.93 to $1.00
• 50-Day Range: $0.81 to $1.35
• 52-Week Range: $0.73 to $1.80
• Volume: 410,418 shs
• Average Volume: 958,015 shs
• Market Capitalization: $90.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.25
• Consensus Rating: Buy

Assertio Stock Analysis - MarketRank™

Assertio scored higher than 63% of companies evaluated by MarketBeat, and ranked 418th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Assertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Assertio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Assertio are expected to grow in the coming year, from ($0.17) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assertio is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assertio is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Assertio has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.38% of the outstanding shares of Assertio have been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assertio does not currently pay a dividend.

Dividend Growth

Assertio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.38% of the outstanding shares of Assertio have been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.75

News Sentiment

Assertio has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Assertio this week, compared to 3 articles on an average week.

Search Interest

14 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.

MarketBeat Follows

9 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Assertio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $69,950.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Assertio is held by insiders.

Percentage Held by Institutions

48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ASRT Stock Analysis - Frequently Asked Questions

How have ASRT shares performed this year?

Assertio's stock was trading at $1.07 at the start of the year. Since then, ASRT shares have decreased by 11.2% and is now trading at $0.95.
View the best growth stocks for 2024 here.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) issued its earnings results on Monday, November, 11th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The firm earned $29.20 million during the quarter, compared to the consensus estimate of $29.29 million. Assertio had a positive trailing twelve-month return on equity of 3.79% and a negative net margin of 54.46%.

Who are Assertio's major shareholders?

Top institutional shareholders of Assertio include Geode Capital Management LLC (1.13%), Empowered Funds LLC (0.45%), Palumbo Wealth Management LLC (0.20%) and XTX Topco Ltd (0.18%). Insiders that own company stock include Daniel A Peisert, Heather L Mason, William Mckee, Jeff L Vacirca, Ajay Patel, Sam Schlessinger, Paul Schwichtenberg and Brendan P O'grady.
View institutional ownership trends.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASRT
• CUSIP: N/A
• CIK: 1808665
• Web: www.assertiotx.com
• Phone: (224) 419-7106
• Fax: 510-744-8001
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.25
• High Stock Price Target: $4.00
• Low Stock Price Target: $2.75
• Potential Upside/Downside: +242.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-331,940,000.00
• Net Margins: -54.46%
• Pretax Margin: -33.94%
• Return on Equity: 3.79%
• Return on Assets: 1.81%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 2.01
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $152.07 million
• Price / Sales: 0.60
• Cash Flow: $0.86 per share
• Price / Cash Flow: 1.11
• Book Value: $1.46 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 95,480,000
• Free Float: 92,423,000
• Market Cap: $90.71 million
• Optionable: Optionable
• Beta: 0.83